2401 4TH AVE., SEATTLE, WA
To Showcase Multispecific Platform at SITC 2026 Annual Meeting
Advances Next-Generation Trispecific Candidate Toward Clinical Development
Shareholder votes
Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Stockholder Meeting Results; Directors Zsolt Harsanyi and Barbara Lo Elected
Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Annual Report to Security Holders
Q2
Q1
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Notice of Exempt Offering of Securities
S-1
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload